Literature DB >> 24683258

Effects of intraperitoneal melatonin on caustic sclerosing cholangitis due to scolicidal solution in a rat model.

Atakan Sezer1, Ahmet Rahmi Hatipoglu1, Ufuk Usta2, Gülay Altun3, Necdet Sut4.   

Abstract

BACKGROUND: Hydatid disease is a worldwide health problem. Treatment is surgical or percutaneous, using scolicidal agents. Caustic sclerosing cholangitis might develop after the contact of scolicidal agents with the biliary ducts. Melatonin, an antioxidant, anti-inflammatory, and anticarcinogenic agent, might be used in the treatment of caustic sclerosing cholangitis due to its possible preventive effects on fibrosis and cell damage.
OBJECTIVE: The aim of the study was to investigate the effects of melatonin on an experimentally developed caustic sclerosing cholangitis with scolicidal solution (formalin) in a rat model.
METHODS: Forty female Sprague-Dawley rats aged 11 to 13 weeks and weighing 250 ± 30 g were randomly assigned to 1 of 4 groups of 10: formalin 5% at 0.5 mL/d + melatonin placebo; formalin placebo + intraperitoneal melatonin 10 mg/kg/d; formalin 5% at 0.5 mL/d + melatonin 10 mg/kg/d; and formalin placebo and melatonin placebo (control). Hepatobiliary function was assessed using dynamic scintigraphy with technetium-99m-mebrofenin on study day 60. The histology of the liver and biliary duct specimens was examined on study day 60. In each group, histopathologic alterations were scored as absent, slight, mild, or severe.
RESULTS: Mean severity scores for parenchymal necrosis in the liver (P < 0.01), portal fibrosis (P < 0.01), biliary duct proliferation (P < 0.001), cholangitis/ pericholangitis (P < 0.01), hyperemia in the biliary ducts (P < 0.01), and fibrosis (P < 0.01) were significantly lower in rats treated with formalin + melatonin compared with those treated with formalin alone. No significant differences were observed between the 3 treatment groups with respect to t½, a parameter used to assess the secretion function of the hepatocytes. However, the t½ was significantly longer in the treatment groups compared with controls (P < 0.001).
CONCLUSION: In this experimental study in a rat model of caustic sclerosing cholangitis, the histopathologic and scintigraphic findings suggested that melatonin is effective in attenuating the damage caused by scolicidal agents on the liver and biliary ducts.

Entities:  

Keywords:  caustic sclerosing cholangitis; hydatid cyst; melatonin; scolicidal solutions

Year:  2010        PMID: 24683258      PMCID: PMC3967282          DOI: 10.1016/j.curtheres.2010.03.004

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  26 in total

Review 1.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Sclerosing cholangitis induced by formaldehyde solution injected into the biliary tree of rats.

Authors:  S Houry; O Languille; M Huguier; J P Benhamou; J Belghiti; S Msika
Journal:  Arch Surg       Date:  1990-08

Review 3.  [Sclerosing cholangitis after the surgical treatment of hepatic echinococcosis].

Authors:  V Tasev
Journal:  Khirurgiia (Sofiia)       Date:  1998

4.  Secondary sclerosing cholangitis: after injection of formaldehyde into hydatid cysts in the liver.

Authors:  E C Tsimoyiannis; E Grantzis; K Moutesidou; E T Lekkas
Journal:  Eur J Surg       Date:  1995-04

5.  Sclerosing cholangitis after surgical treatment of hepatic echinococcal cysts. Report of three cases.

Authors:  J Terés; J Gomez-Moli; M Bruguera; J Visa; J M Bordas; C Pera
Journal:  Am J Surg       Date:  1984-11       Impact factor: 2.565

6.  Presence of melatonin in the human hepatobiliary-gastrointestinal tract.

Authors:  M Messner; G Huether; T Lorf; G Ramadori; H Schwörer
Journal:  Life Sci       Date:  2001-06-22       Impact factor: 5.037

7.  Efficacy of melatonin as protectant against oxidative stress and structural changes in liver tissue in pinealectomized rats.

Authors:  Engin Sahna; Hakan Parlakpinar; Nigar Vardi; Yilmaz Ciğremis; Ahmet Acet
Journal:  Acta Histochem       Date:  2004       Impact factor: 2.479

8.  The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia.

Authors:  Sylvia Aust; Theresia Thalhammer; Susanne Humpeler; Walter Jäger; Martin Klimpfinger; Gerhard Tucek; Peter Obrist; Wolfgang Marktl; Edward Penner; Cem Ekmekcioglu
Journal:  J Pineal Res       Date:  2004-01       Impact factor: 13.007

9.  Echinococcosis: costs, losses and social consequences of a neglected zoonosis.

Authors:  G Battelli
Journal:  Vet Res Commun       Date:  2009-09       Impact factor: 2.459

10.  The effects of melatonin on postoperative intraabdominal adhesion formation.

Authors:  Ahmet Hatipoğlu; Zeliha Türkyilmaz; Selva Mert
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

View more
  3 in total

1.  Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

Authors:  Nan Wu; Fanyin Meng; Tianhao Zhou; Yuyan Han; Lindsey Kennedy; Julie Venter; Heather Francis; Sharon DeMorrow; Paolo Onori; Pietro Invernizzi; Francesca Bernuzzi; Romina Mancinelli; Eugenio Gaudio; Antonio Franchitto; Shannon Glaser; Gianfranco Alpini
Journal:  FASEB J       Date:  2017-06-20       Impact factor: 5.191

2.  Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors.

Authors:  Anastasia Renzi; Shannon Glaser; Sharon Demorrow; Romina Mancinelli; Fanyin Meng; Antonio Franchitto; Julie Venter; Mellanie White; Heather Francis; Yuyan Han; Domenico Alvaro; Eugenio Gaudio; Guido Carpino; Yoshiyuki Ueno; Paolo Onori; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-07-14       Impact factor: 4.052

Review 3.  Protective role of melatonin in early-stage and end-stage liver cirrhosis.

Authors:  Chenxia Hu; Lingfei Zhao; Jingjing Tao; Lanjuan Li
Journal:  J Cell Mol Med       Date:  2019-09-02       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.